Wall Street analysts expect that Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) will post earnings per share of $0.25 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Supernus Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.28 and the lowest estimate coming in at $0.24. Supernus Pharmaceuticals posted earnings of $0.18 per share in the same quarter last year, which suggests a positive year over year growth rate of 38.9%. The company is scheduled to issue its next earnings report on Tuesday, August 1st.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year earnings of $1.08 per share for the current financial year, with EPS estimates ranging from $0.89 to $1.50. For the next financial year, analysts anticipate that the company will post earnings of $1.63 per share, with EPS estimates ranging from $1.45 to $2.01. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by $0.03. The firm had revenue of $57.58 million for the quarter, compared to analyst estimates of $57.91 million. Supernus Pharmaceuticals had a return on equity of 31.79% and a net margin of 42.46%.

Several brokerages have recently commented on SUPN. Piper Jaffray Companies upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $30.00 to $44.00 in a research report on Thursday, June 1st. Jefferies Group LLC boosted their target price on shares of Supernus Pharmaceuticals from $35.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, May 31st. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 4th. Cowen and Company boosted their target price on shares of Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, May 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $31.00 target price on shares of Supernus Pharmaceuticals in a research report on Tuesday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $33.43.

In related news, VP Padmanabh P. Bhatt sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The shares were sold at an average price of $39.86, for a total transaction of $398,600.00. Following the completion of the transaction, the vice president now directly owns 27,500 shares in the company, valued at approximately $1,096,150. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 11,806 shares of the company’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $32.59, for a total transaction of $384,757.54. Following the transaction, the vice president now owns 45,500 shares of the company’s stock, valued at $1,482,845. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 83,806 shares of company stock valued at $2,813,038. 6.70% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter valued at about $127,000. Pacad Investment Ltd. acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $124,000. Fortaleza Asset Management Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter valued at about $160,000. State of Alaska Department of Revenue boosted its position in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 170 shares during the period. Finally, OppenheimerFunds Inc. acquired a new position in shares of Supernus Pharmaceuticals during the first quarter valued at about $205,000. Hedge funds and other institutional investors own 92.08% of the company’s stock.

Supernus Pharmaceuticals (NASDAQ:SUPN) traded up 3.26% during mid-day trading on Wednesday, hitting $42.75. 606,255 shares of the stock traded hands. The firm’s 50-day moving average price is $35.99 and its 200-day moving average price is $29.53. The firm has a market cap of $2.15 billion, a P/E ratio of 23.00 and a beta of 1.76. Supernus Pharmaceuticals has a 52 week low of $17.25 and a 52 week high of $42.85.

TRADEMARK VIOLATION NOTICE: “Brokerages Expect Supernus Pharmaceuticals, Inc. (SUPN) to Announce $0.25 EPS” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/06/21/brokerages-expect-supernus-pharmaceuticals-inc-supn-to-announce-0-25-eps.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.